1
Malini Batheja, Ph.D
Behl Charanjit R, Dua Ramneik, Gupta Malini, Rahman Parvin, Romeo Vincent D: Method for increasing the solubility of morphine and pharmaceutical compositions prepared therefrom. Nastech Pharmaceutical Company, BODNER Gerald T, December 21, 2000: WO/2000/076507

Methods are disclosed for increasing the solubility of morphine through the use of organic acid or its salts as a solubilizing agent. Particularly useful as solubilizing agents are salts of carboxylic acids, such as gluconate, acetate, citrate, lactate, tartrate, aspartate, fumarate, malate, maleate ...


2
Colin D Granger, Thomas H Simon: Misuse-resistive transdermal opioid dosage form. Warner Lambert Company, Richard S Bullitt, September 22, 1992: US05149538 (239 worldwide citation)

A misuse-resistive dosage form for the transdermal delivery of opioid comprises, in combination, 1) one or more opioid permeable to the skin, 2) delivery means permeable to said opioid, 3) one or more antagonist for said opioid releasable upon ingestion or solvent immersion, and 4) impermeable barri ...


3
Anwar A Hussain: Method of administering narcotic antagonists and analgesics and novel dosage forms containing same. University of Kentucky Research Foundation, Burns Doane Swecker & Mathis, August 7, 1984: US04464378 (197 worldwide citation)

The invention provides a novel method of administering narcotic antagonists, narcotic analgesics and related compounds, and novel dosage forms containing those compounds which are adapted for nasal administration. The nasal dosage forms disclosed include solutions, suspensions, gels and ointments. E ...


4
David J Mayer, Donald D Price, Jianren Mao, John W Lyle: Method for the treatment of pain. Virginia Commonwealth University, Dilworth & Barrese, March 26, 1996: US05502058 (171 worldwide citation)

A method of alleviating pain such as neuropathic pain or acute inflammatory pain is provided which comprises administering to a mammal that is either exhibiting pain or is about to be subjected to a pain-causing event a pain alleviating/pain suppressing amount of at least one nontoxic antagonist for ...


5
Oshlack Benjamin, Chasin Mark: Orally administrable opioid formulations having extended duration of effect.. Euro Celtique, April 12, 1995: EP0647448-A1 (161 worldwide citation)

Sustained release oral solid dosage forms of opioid analgesics are provided as multiparticulate systems which are bioavailable and which provide effective blood levels of the opioid analgesic for at least about 24 hours. A unit dose of the opioid analgesic contains a plurality of substrates includin ...


6
Vijai Kumar, David Dixon, Divya Tewari, Dilip B Wadgaonkar: Methods and compositions for deterring abuse of opioid containing dosage forms. Acura Pharmaceuticals, Morgan Lewis & Bockius, April 10, 2007: US07201920 (144 worldwide citation)

This invention relates to an abuse deterrent dosage form of opioid analgesics, wherein an analgesically effective amount of opioid analgesic is combined with a polymer to form a matrix.


7
Philip S Portoghese, Akira E Takemori: Delta opioid receptor antagonists to block opioid agonist tolerance and dependence. Regents of the University of Minnesota, Warren D Woessner, October 4, 1994: US05352680 (119 worldwide citation)

A motion provided to alleviate the tolerance to, or dependence on, an opiate analgesic, by the administration of an effective amount of a selective delta opioid receptor antagonist to a human patient in need of such treatment.


8
Joseph F Foss, Michael F Roizen, Jonathan Moss, Chun Su Yuan, William Drell: Use of methylnaltrexone and related compounds. Arch Development Corporation, UR Labs, Christie Parker & Hale, October 26, 1999: US05972954 (118 worldwide citation)

A method for preventing or treating opioid induced side effects including dysphoria, pruritus and urinary retention and non-opioid induced changes in gastrointestinal motility. The method comprises administering methylnaltrexone or another quaternary derivative of noroxymorphone to a patient prior t ...


9
Morella Angel Mario, Fisher Mark Christopher: Sustained release pharmaceutical composition.. Faulding F H &, July 11, 1990: EP0377518-A2 (118 worldwide citation)

A sustained release pharmaceutical pellet composition suitable for treating pain-associated conditions in patients comprises a core element including at least one active ingredient of high solubility; and a core coating for the core element which is partially soluble at a highly acidic pH to provide ...


10
David J Mayer, Donald D Price, Jianren Mao, John W Lyle: Method for the treatment of chronic pain. Virginia Commonwealth University Medical College of Virginia, Dilworth & Barrese, October 4, 1994: US05352683 (108 worldwide citation)

Chronic pain is alleviated in a mammal suffering therefrom by administering to the mammal a chronic pain alleviating amount of a nontoxic N-methyl-D-aspartate receptor antagonist such as dextromethorphan, dextrorphan, ketamine or pharmaceutically acceptable salt thereof, alone or in combination with ...